160 related articles for article (PubMed ID: 19328647)
1. [Biotherapies: toward a second revolution?].
Mouthon L
Presse Med; 2009 May; 38(5):746-8. PubMed ID: 19328647
[No Abstract] [Full Text] [Related]
2. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
Graves JE; Nunley K; Heffernan MP
J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
[TBL] [Abstract][Full Text] [Related]
3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
[No Abstract] [Full Text] [Related]
4. Therapy with immunoglobulin: applications for monoclonal antibodies.
Stowell CP
J Infus Nurs; 2006; 29(3 Suppl):S29-44. PubMed ID: 16878853
[TBL] [Abstract][Full Text] [Related]
5. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
[No Abstract] [Full Text] [Related]
6. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
[No Abstract] [Full Text] [Related]
7. [Biological treatment of multiple sclerosis].
Sørensen PS; Sellebjerg F
Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
[TBL] [Abstract][Full Text] [Related]
8. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
9. Engineered antibodies act as targeted therapies in cancer treatment.
Mohindru M; Verma A
Indian J Pediatr; 2005 Nov; 72(11):943-7. PubMed ID: 16391449
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
11. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
12. Bevacizumab in ophthalmology: the controversy moves forward.
Gillies MC
Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
[No Abstract] [Full Text] [Related]
13. [Perspectives in clinical immunology].
Rolla G; Ferrero N; Bergia R; Guida G
Recenti Prog Med; 2006 Dec; 97(12):787-96. PubMed ID: 17252738
[TBL] [Abstract][Full Text] [Related]
14. [2/2 The other biotherapies].
Fournel C; Medjoub M; Limat S; Woronoff-Lemsi MC
Soins; 2007 Nov; (720):59-61. PubMed ID: 18376755
[No Abstract] [Full Text] [Related]
15. [Anti-angiogenetic agents for solid tumors].
Blay JY
Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
[No Abstract] [Full Text] [Related]
16. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
Heier JS
Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361
[No Abstract] [Full Text] [Related]
17. Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
Cole A
BMJ; 2007 Sep; 335(7617):416-7. PubMed ID: 17762016
[No Abstract] [Full Text] [Related]
18. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
19. Costly cancer drugs trigger proposals to modify clinical trial design.
Schmidt C
J Natl Cancer Inst; 2009 Dec; 101(24):1662-4. PubMed ID: 19933943
[No Abstract] [Full Text] [Related]
20. Disease-modifying antirheumatic drugs: enhancing efficacy by combination.
Schnabel A
Lancet; 2004 Feb; 363(9410):670-1. PubMed ID: 15001319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
